Action PMCB PHARMACYTE BIOTECH, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues PharmaCyte Biotech, Inc.

Actions

PMCB

US71715X2036

Temps Différé Nasdaq
Autres places de cotation
 15:48:22 28/06/2024 		Varia. 5j. Varia. 1 janv.
2,06 USD -0,96 % Graphique intraday de PharmaCyte Biotech, Inc. +5,64 % -4,63 %
18/03 PharmaCyte Biotech, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois se terminant le 31 janvier 2024 CI
2023 PharmaCyte Biotech, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 octobre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
MyMD Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc.
MyMD Pharmaceuticals, Inc. amended terms of the transaction
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
MyMD Pharmaceuticals, Inc. announced that it expects to receive $14 million in funding from PharmaCyte Biotech, Inc.
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023
Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors
Femasys Inc. announces tranche update
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc.
PharmaCyte Biotech : Change in Certifying Accountants - Form 8-K
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023
PharmaCyte Biotech : Certificate of Incorporation/Bylaws - Form 8-K
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PMCB
  4. Actualités PharmaCyte Biotech, Inc.
  5. Autres langues